Authors: Courtney Woolsey, Viktoriya Borisevich, Alyssa C. Fears, Krystle N. Agans, Daniel J. Deer, Abhishek N. Prasad, Rachel O’Toole, Stephanie L. Foster, Natalie S. Dobias, Joan B. Geisbert, Karla A. Fenton, Robert W. Cross, Thomas W. Geisbert
Year: 2024
Journal: The Journal of Clinical Investigation
DOI: 10.xxxx/xxxxx
Summary#
This paper reports on a recombinant vesicular stomatitis virus–based vaccine that provides long-lasting immunity against Nipah virus disease in African green monkeys.
Key Findings#
- rVSV-ΔG-NiVBG vaccine protects 100% of nonhuman primates from NiV-associated lethality within a week
- All immunized AGMs (whether receiving a single dose or prime-boosted) survived with no detectable clinical signs or NiV replication
- Transcriptomic analyses indicated that adaptive immune signatures correlated with vaccine-mediated protection
Methodology#
- Study Type: Experimental
- Sample Size: African green monkeys (AGMs)
- Geographic Focus: Galveston, Texas, USA
Topics#
Vaccines, Nipah Virus, Immunology
Relevance#
The development of a long-lasting immunity vaccine for Nipah virus could be crucial in preventing future outbreaks and pandemics.